Camille Watson
Psychiatric/Mental Health · Austin, TXNPI 1811096324
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by AbbVie at 41.2% of the total. Reporting peaked in 2023 at $15,674 and has fallen 81.0% since, to $2,985 in 2025. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 763 payments — averaging $44.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Otsuka America Pharmaceutical, Inc.$10K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Lundbeck LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$789
- plus $4K from 20 others
What the payments were for
- Speaking & faculty fees$18,49554%
- Travel & lodging$1,7025%
- Food & beverage$13,85041%
- Education$560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 138 | $14,050 |
| Otsuka America Pharmaceutical, Inc. | 88 | $9,595 |
| Alkermes, Inc. | 137 | $2,490 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 97 | $1,876 |
| Lundbeck LLC | 62 | $1,102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $789 |
| Axsome Therapeutics, Inc. | 20 | $608 |
| Neurocrine Biosciences, Inc. | 26 | $499 |
| Ironshore Pharmaceuticals Inc. | 28 | $468 |
| Sunovion Pharmaceuticals Inc. | 38 | $439 |
| Corium, LLC | 23 | $432 |
| Teva Pharmaceuticals USA, Inc. | 16 | $431 |
| E.r. Squibb & Sons, L.L.C. | 3 | $246 |
| Boehringer Ingelheim | 2 | $230 |
| Noven Therapeutics, LLC | 7 | $131 |
| Biogen | 1 | $121 |
| Eisai Inc. | 5 | $87 |
| Supernus Pharmaceuticals, Inc. | 5 | $84 |
| Collegium Pharmaceutical, Inc. | 5 | $82 |
| Idorsia Pharmaceuticals US Inc | 4 | $81 |
| Neos Therapeutics, LP | 5 | $74 |
| Johnson & Johnson | 3 | $51 |
| Jazz Pharmaceuticals Inc. | 2 | $41 |
| Tris Pharma Inc | 2 | $38 |
| Alfasigma USA, Inc. | 1 | $32 |
| Acadia Pharmaceuticals Inc | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$11,950
- REXULTI$7,854
- ARISTADA$468
- Auvelity$238
- COBENFY$195
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- ARISTADA INITIO$117
- Austedo XR$103
How this compares
$34,103 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 14 | $188,497 |
| Abilify AsimtufiiAripiprazole | 11 | $48,705 |
| FanaptIloperidone | 20 | $40,932 |
| VraylarCariprazine Hcl | 23 | $31,293 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 165 | $6,765 |
| Lamotrigine | 153 | $2,841 |
| Asenapine Maleate | 12 | $2,760 |
| Lurasidone Hcl | 15 | $2,661 |
| Aripiprazole | 85 | $1,523 |
| Sertraline Hcl | 91 | $1,169 |
| Trazodone Hcl | 52 | $1,149 |
| Oxcarbazepine | 16 | $1,107 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $1,070 |
| Divalproex Sodium ErDivalproex Sodium | 30 | $1,004 |
| Clonazepam | 116 | $804 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $431 | $188,49714 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii | $9,595 | $48,70511 claims |
| AbbVieVraylar | $14,050 | $31,29323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Austin
- Jaime Nelson DensonAustin$88K
- Suzanne GranthamAustin$31K
- Lin CaiAustin$16K
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.